Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment - PubMed (original) (raw)

Review

Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment

Sarah D Cramer et al. Blood. 2016.

Abstract

Increased understanding of pediatric acute lymphoblastic leukemia (ALL) pathobiology has led to dramatic improvements in patient survival. However, there is still a need to develop targeted therapies to enable reduced chemotherapy intensity and to treat relapsed patients. The interleukin-7 receptor α (IL-7Rα) signaling pathways are prime therapeutic targets because these pathways harbor genetic aberrations in both T-cell ALL and B-cell precursor ALL. Therapeutic targeting of the IL-7Rα signaling pathways may lead to improved outcomes in a subset of patients.

PubMed Disclaimer

Figures

Figure 1

IL-7Rα pathway mutations provide potential targets for acute lymphoblastic leukemia therapy. In both T-ALL and BCP-ALL, mutations can occur at many points within the IL-7Rα signaling pathways (A). Aberrant signaling through these pathways offers multiple potential therapeutic targets (B).

Similar articles

• A fully human anti-IL-7Rα antibody promotes antitumor activity against T-cell acute lymphoblastic leukemia.
  Akkapeddi P, Fragoso R, Hixon JA, Ramalho AS, Oliveira ML, Carvalho T, Gloger A, Matasci M, Corzana F, Durum SK, Neri D, Bernardes GJL, Barata JT. Akkapeddi P, et al. Leukemia. 2019 Sep;33(9):2155-2168. doi: 10.1038/s41375-019-0434-8. Epub 2019 Mar 8. Leukemia. 2019. PMID: 30850736 Free PMC article.
• Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling.
  Brown VI, Hulitt J, Fish J, Sheen C, Bruno M, Xu Q, Carroll M, Fang J, Teachey D, Grupp SA. Brown VI, et al. Cancer Res. 2007 Oct 15;67(20):9963-70. doi: 10.1158/0008-5472.CAN-06-4704. Cancer Res. 2007. PMID: 17942929
• CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.
  Angelova E, Audette C, Kovtun Y, Daver N, Wang SA, Pierce S, Konoplev SN, Khogeer H, Jorgensen JL, Konopleva M, Zweidler-McKay PA, Medeiros LJ, Kantarjian HM, Jabbour EJ, Khoury JD. Angelova E, et al. Haematologica. 2019 Apr;104(4):749-755. doi: 10.3324/haematol.2018.205252. Epub 2018 Oct 25. Haematologica. 2019. PMID: 30361418 Free PMC article. Clinical Trial.
• Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma.
  DuVall AS, Wesevich A, Larson RA. DuVall AS, et al. Curr Hematol Malig Rep. 2023 Dec;18(6):217-225. doi: 10.1007/s11899-023-00706-7. Epub 2023 Jul 25. Curr Hematol Malig Rep. 2023. PMID: 37490229 Review.
• IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update.
  Oliveira ML, Akkapeddi P, Ribeiro D, Melão A, Barata JT. Oliveira ML, et al. Adv Biol Regul. 2019 Jan;71:88-96. doi: 10.1016/j.jbior.2018.09.012. Epub 2018 Sep 19. Adv Biol Regul. 2019. PMID: 30249539 Free PMC article. Review.

Cited by

• Facts and Challenges in Immunotherapy for T-Cell Acute Lymphoblastic Leukemia.
  Bayón-Calderón F, Toribio ML, González-García S. Bayón-Calderón F, et al. Int J Mol Sci. 2020 Oct 16;21(20):7685. doi: 10.3390/ijms21207685. Int J Mol Sci. 2020. PMID: 33081391 Free PMC article. Review.
• Dual effect of IL-7/IL-7R signalling on the osteoimmunological system: a potential therapeutic target for rheumatoid arthritis.
  Xu H, Cai L, Li Z, Zhang L, Wang G, Xie R, Jiang Y, Yuan Y, Nie H. Xu H, et al. Immunology. 2021 Sep;164(1):161-172. doi: 10.1111/imm.13351. Epub 2021 Jun 2. Immunology. 2021. PMID: 33934341 Free PMC article.
• The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy.
  Wang C, Kong L, Kim S, Lee S, Oh S, Jo S, Jang I, Kim TD. Wang C, et al. Int J Mol Sci. 2022 Sep 8;23(18):10412. doi: 10.3390/ijms231810412. Int J Mol Sci. 2022. PMID: 36142322 Free PMC article. Review.
• Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma.
  Silva A, Almeida ARM, Cachucho A, Neto JL, Demeyer S, de Matos M, Hogan T, Li Y, Meijerink J, Cools J, Grosso AR, Seddon B, Barata JT. Silva A, et al. Blood. 2021 Sep 23;138(12):1040-1052. doi: 10.1182/blood.2019000553. Blood. 2021. PMID: 33970999 Free PMC article.
• Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies.
  Lodewijckx I, Cools J. Lodewijckx I, et al. Pharmaceuticals (Basel). 2021 May 8;14(5):443. doi: 10.3390/ph14050443. Pharmaceuticals (Basel). 2021. PMID: 34066732 Free PMC article. Review.

References

1. 1. Gutierrez A, Silverman L. Acute lymphoblastic leukemia. In: Orkin S, Fisher D, Ginsburg D, Look A, Lux S, Nathan D, editors. Nathan and Oski’s Hematology and Oncology of Infancy and Childhood. Vol. 2. Philadelphia: Elsevier Saunders; 2015. pp. 1527–1554.
2. 1. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med. 2009;360(26):2730–2741. - PMC - PubMed
3. 1. Nguyen K, Devidas M, Cheng SC, et al. Children’s Oncology Group. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study. Leukemia. 2008;22(12):2142–2150. - PMC - PubMed
4. 1. Freyer DR, Devidas M, La M, et al. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children’s Oncology Group. Blood. 2011;117(11):3010–3015. - PMC - PubMed
5. 1. Mullighan CG, Hunger SP. Therapy of pediatric ALL: from Bowie to Obama. Blood. 2013;122(15):2531–2532. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • scite Smart Citations